Want to see EQ full AI Analyst Report?
Top Page
Equillium
(NASDAQ:EQ)
Select Model
Select Model
Rating:46Neutral
Price Target:
$1.50
▼(-31.19% Downside)
Action:Reiterated
Date:08/18/26
The score is primarily held back by weak financial performance (zero TTM revenue, ongoing net losses, and sustained cash burn), partially offset by low leverage and meaningful equity on the balance sheet. Technicals are neutral to slightly weak, and valuation is constrained by negative earnings (negative P/E) with no dividend yield provided.
Positive Factors
Low leverage
Very low debt limits near-term interest and refinancing pressure, giving Equillium greater financial flexibility than a highly leveraged biotech. This conservative capital structure can help preserve strategic options while clinical programs advance, although it does not eliminate the need for funding.
Negative Factors
Zero revenue and continuing losses
The absence of current revenue means operations are not yet self-funding, while sizable net and operating losses continue to consume the company’s financial resources. Until a program generates commercial or collaboration income, earnings quality and the ability to fund development internally remain weak.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage
Very low debt limits near-term interest and refinancing pressure, giving Equillium greater financial flexibility than a highly leveraged biotech. This conservative capital structure can help preserve strategic options while clinical programs advance, although it does not eliminate the need for funding.
Read all positive factors
Equillium (EQ) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$109.06M
Dividend YieldN/A
Average Volume (3M)510.23K
Price to Earnings (P/E)―
Beta (1Y)-0.46
Revenue Growth-100.00%
EPS Growth64.23%
CountryUS
Employees14
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.26
Shares Outstanding63,408,080
10 Day Avg. Volume750,302
30 Day Avg. Volume510,227
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)4.98
Price to Sales (P/S)0.00
P/FCF Ratio-6.25
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$11.60Price Target Upside432.11% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.23
Revenue Forecast (FY)N/A
Equillium Business Overview & Revenue Model
Company Description
Equillium, Inc. is a clinical-stage biopharmaceutical company focused on developing and bringing to market products designed to address severe autoimmune and inflammatory (immuno-inflammatory) disorders where current treatment options are insuffic...
How the Company Makes Money
Equillium is a clinical-stage biotech company and, as such, it does not primarily generate recurring revenue from marketed products. Its cash generation has historically depended on external funding and collaboration-related inflows rather than pr...
Equillium Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 41.09M | 36.08M | 15.76M | 0.00 |
| Gross Profit | -47.00K | -116.00K | 41.09M | 36.08M | 15.76M | -72.00K |
| EBITDA | -18.35M | -22.28M | -7.57M | -12.14M | -61.26M | -37.91M |
| Net Income | -18.01M | -22.40M | -8.07M | -13.34M | -62.43M | -38.98M |
Balance Sheet | ||||||
| Total Assets | 58.67M | 31.89M | 25.60M | 50.53M | 78.42M | 85.41M |
| Cash, Cash Equivalents and Short-Term Investments | 57.16M | 30.28M | 22.57M | 40.87M | 71.02M | 80.71M |
| Total Debt | 584.00K | 719.00K | 384.00K | 824.00K | 10.19M | 11.79M |
| Total Liabilities | 2.65M | 3.29M | 6.54M | 27.96M | 46.48M | 18.90M |
| Stockholders Equity | 56.02M | 28.60M | 19.06M | 22.57M | 31.94M | 66.50M |
Cash Flow | ||||||
| Free Cash Flow | -20.09M | -22.79M | -19.11M | -21.83M | -9.01M | -32.14M |
| Operating Cash Flow | -19.97M | -22.75M | -19.03M | -21.78M | -8.73M | -32.08M |
| Investing Cash Flow | -106.00K | 4.46M | 13.81M | -4.76M | 18.68M | 27.41M |
| Financing Cash Flow | 65.74M | 30.43M | 164.00K | -9.23M | -1.22M | 31.06M |
Equillium Technical Analysis
Negative
2.18
Price Trends
2.24
Negative
2.45
Negative
2.06
Negative
Market Momentum
-0.16
Positive
31.68
Neutral
8.83
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For EQ, the sentiment is Negative. The current price of 2.18 is above the 20-day moving average (MA) of 2.09, below the 50-day MA of 2.24, and above the 200-day MA of 2.06, indicating a bearish trend. The MACD of -0.16 indicates Positive momentum. The RSI at 31.68 is Neutral, neither overbought nor oversold. The STOCH value of 8.83 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for EQ.
Equillium Risk Analysis
Equillium disclosed 86 risk factors in its most recent earnings report. Equillium reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Equillium Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $131.19M | -4.03 | 168.68% | ― | ― | 67.07% | |
48 Neutral | $64.07M | -5.34 | -144.31% | ― | -26.89% | 56.50% | |
47 Neutral | $318.42M | -4.91 | -75.35% | ― | 220.34% | 55.73% | |
46 Neutral | $109.06M | -6.52 | -41.15% | ― | -100.00% | 64.23% | |
43 Neutral | $260.49M | -0.92 | 185.30% | ― | -56.25% | 30.97% |
* Healthcare Sector Average
EQ
Equillium
1.67
0.21
14.38%
NRXP
NRX Pharmaceuticals
3.00
-0.25
-7.85%
STRO
Sutro Biopharma
15.98
7.23
82.63%
HYFT
MindWalk Holdings
1.38
-0.35
-20.23%
PRLD
Prelude Therapeutics
3.88
2.51
182.85%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.